Colorcon opens new formulation services facility in Bogota, Colombia
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects.
Colorcon has announced the opening of a new Technical Service, Laboratory and Conference Facility in Bogotá, Colombia, to support market growth and customers across the Andean countries, Central America and the Caribbean. The new facility is strategically located close to transportation hubs to service the pharmaceutical industry across this region.
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects. Carlos LaCruz, Regional Sales Manager explains the importance of this facility to the region “The laboratory is fully equipped to handle Level II and Level IV APIs, for research scale solid dose development. This capability is of particular importance for our customers who require this type of equipment and containment capabilities. We can provide specialized support to accelerate development and commercialization of robust, high quality pharmaceutical drug formulations”.
Plinio Sandoval, Regional Technical Manager stated: “To shorten customer’s formulation development time, Colorcon has invested in new‐instrumented equipment, including high shear granulation, an instrumented press machine, advanced film coating equipment and USP dissolution apparatus. Access to this advanced technology and analytical tools enables more robust formulation development, provides release profiles and ultimately better prediction for scale‐up to manufacturing.”
The Technical Center provides the capacity to increase the educational programs offered, with additional Colorcon Coating and Formulation Schools included to the 2016 schedule; plus a new Formulation School for Matrices addressing the markets’ continuing interest for modified release products.
Perry Cozzone, President — Americas added: “This investment demonstrates Colorcon’s continued commitment to reducing our customer’s time to market and making a positive contribution to their manufacturing quality and production efficiency. It reinforces our dedication to providing best‐in‐class products and services through a network of laboratories positioned close to our customers. The combination of our high quality products and this unprecedented service model is the value of Colorcon.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.